Quality of Life, Toxicity Weighed Most by Patients When Choosing Metastatic Breast Cancer Treatment
Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey.
Source: onclive.com